Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736460 | 0.83 | TRPV4 (0.39) | GRM5ROCK2KCNJ1OPRM1SIGMAR1 | |
| SCHEMBL735499 | 0.82 | GRM5 (0.41) | GRM5KCNJ1OPRM1SIGMAR1 | |
| SCHEMBL737418 | 0.82 | SIGMAR1 (0.44) | OPRM1SIGMAR1CYP3A4CYP2C19 | |
| SCHEMBL735671 | 0.80 | CHRNB2 (0.46) | OPRM1SIGMAR1 | |
| SCHEMBL736367 | 0.78 | OPRM1 (0.40) | ROCK2KCNJ1OPRM1SIGMAR1OPRL1 | |
| SCHEMBL16430239 | 0.78 | KCNJ1 (0.55) | KCNJ1 | |
| SCHEMBL736045 | 0.77 | CHRNB2 (0.44) | KCNJ1OPRM1SIGMAR1OPRL1 | |
| SCHEMBL738702 | 0.77 | ALOX5 (0.44) | GRM5ROCK2KCNJ1OPRM1SIGMAR1 | |
| SCHEMBL736593 | 0.77 | ALDH1A1 (0.50) | GRM5OPRM1SIGMAR1CYP3A4CYP2C19 | |
| SCHEMBL736127 | 0.77 | ADRB1 (0.46) | ROCK2OPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | GRM5 263/4885ROCK2 3313/4885KCNJ1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.